OTCMKTS:BSTG Biostage (BSTG) Stock Price, News & Analysis $4.45 0.00 (0.00%) As of 07/24/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Biostage Stock (OTCMKTS:BSTG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biostage alerts:Sign Up Key Stats Today's Range$4.45▼$4.4550-Day Range$4.45▼$4.4552-Week Range$4.45▼$4.45VolumeN/AAverage Volume1,847 shsMarket Capitalization$61.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Biostage, Inc. (OTCMKTS: BSTG) is a development‐stage regenerative medicine company dedicated to creating implantable, tissue‐engineered medical devices designed to treat severe organ disorders. The company’s proprietary platform integrates bioscaffolds with a patient’s own cells to produce living implants that can restore structure and function in damaged tissues. Biostage’s mission focuses on addressing unmet medical needs in life‐threatening conditions where conventional therapies offer limited efficacy. The company’s lead product candidate, the Neo‐Esophagus, is designed to replace or repair sections of the esophagus damaged by congenital defects, cancer resections, or severe trauma. Biostage also has earlier‐stage programs targeting airway reconstruction, leveraging the same scaffold‐and‐autologous‐cell technology. By using a patient’s own cells, the company aims to reduce the risk of rejection and eliminate the need for long‐term immunosuppression. Biostage has secured regulatory clearance to initiate clinical studies for its esophageal repair device and continues to advance its pipeline through preclinical development. Founded in 2003 under the name Tengion, the company rebranded as Biostage in 2018 to reflect its focus on true tissue regeneration and organ reconstruction. Headquartered in Cambridge, Massachusetts, Biostage operates within the United States, collaborating with research institutions and clinical investigators to drive its development programs forward. The company is led by a management team with extensive experience in biotechnology, medical devices, and regenerative medicine, positioning Biostage to translate its novel platform into potential therapies for patients with critical organ needs.AI Generated. May Contain Errors. Read More Receive BSTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biostage and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSTG Stock News HeadlinesBiostage stock initiated with Buy rating at TD Cowen on specialty growthJune 24, 2025 | investing.comJefferies maintains Buy on Biostage shares with raised target amid bullish growth outlookJanuary 22, 2025 | msn.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.September 10 at 2:00 AM | Weiss Ratings (Ad)Harvard Apparatus Regenerative Technology Inc (HRGN)January 5, 2024 | investing.comHRGN Harvard Apparatus Regenerative Technology Inc.August 22, 2023 | seekingalpha.comBiostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)July 20, 2023 | finance.yahoo.comBiostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal DiseaseJuly 18, 2023 | finance.yahoo.comBiostage CEO Awarded $1.07M Worth of Stock OptionsJuly 11, 2023 | benzinga.comSee More Headlines BSTG Stock Analysis - Frequently Asked Questions How have BSTG shares performed this year? Biostage's stock was trading at $4.45 at the beginning of the year. Since then, BSTG stock has increased by 0.0% and is now trading at $4.45. How were Biostage's earnings last quarter? Biostage, Inc. (OTCMKTS:BSTG) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.14) EPS for the quarter. How do I buy shares of Biostage? Shares of BSTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biostage own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biostage investors own include Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), Ashford Hospitality Trust (AHT), Assertio (ASRT), Adaptimmune Therapeutics (ADAP), PlayAGS (AGS) and Akebia Therapeutics (AKBA). Company Calendar Last Earnings8/13/2020Today9/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:BSTG CIK1563665 Webwww.biostage.com Phone(744) 233-7300Fax774-233-7302Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.07 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-174.43% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-17.12Miscellaneous Outstanding Shares13,882,000Free Float11,758,000Market Cap$61.77 million OptionableNot Optionable Beta-1.02 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:BSTG) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemTucked away outside San Antonio sits a facility most Americans don’t know exists. It’s not mining gold or o...True Market Insiders | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biostage, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biostage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.